<sup>99m</sup>Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow‐up of clinically nonfunctioning pituitary adenomas after radiotherapy

Colao, Annamaria; Ferone, Diego; Lombardi, Gaetano; Lastoria, Secondo

doi:10.1046/j.1365-2265.2002.01537.x

Cited by 8 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall sensitivity of 99m Tc(V)-DMSA and 99m Tc-HYNIC-TOC, by the qualitative scintigraphic analysis described, was significantly lower, and is consistent with previous studies that concluded that scintigraphy with these tracers was not sufficiently sensitive for the evaluation of patients with secreting PAs 44,50.…”

Section: Discussionsupporting

confidence: 89%

Clinical usefulness of 99mTc-HYNIC-TOC, 99mTc(V)-DMSA, and 99mTc-MIBI SPECT in the evaluation of pituitary adenomas

Vukomanovic¹,

Matović²,

Doknic

et al. 2019

Nuclear Medicine Communications

View full text Add to dashboard Cite

BackgroundThe aim of this study was to evaluate the behavioral uptake and ability to diagnose pituitary adenoma (PA) using tumor-seeking radiopharmaceuticals, and to provide a semiquantitative analysis of tracer uptake in the pituitary region.Patients and methodsThe study included 33 (13 hormonally active and 20 nonfunctioning) patients with PA and 45 control participants without pituitary involvement. All patients (n=78) underwent single photon emission computed tomography (SPECT) imaging with technetium-99m-labeled hydrazinonicotinyl-tyr3-octreotide (99mTc-HYNIC-TOC), dimercaptosuccinic acid (99mTc(V)-DMSA) and hexakis-2-methoxyisobutylisonitrile (99mTc-MIBI). A semiquantitative analysis of abnormal uptake was carried out by drawing identical regions of interest over the pituitary area and the normal brain on one transverse section that shows the lesion most clearly. The pituitary uptake to normal brain uptake (P/B) ratio was calculated in all cases.ResultsThe result of this study confirms that the SPECT semiquantitative method, with all three tracers, showed statistically significant differences between the PA group and the controls. However, 99mTc-HYNIC-TOC scintigraphy could have the highest diagnostic yield because of the smallest overlap between the P/B ratios between adenoma versus nonadenoma participants (the receiver operating characteristic curve P/B ratio cut-off value was 13.08). In addition, only 99mTc-MIBI SPECT have the diagnostic potential to detect secreting PAs, with statistically significant differences between groups (P<0.001), with an receiver operating characteristic curve P/B ratio cut-off value of 16.72.ConclusionA semiquantitative analysis of increased focal tracer uptake in the sellar area showed that 99mTc-HYNIC-TOC is a highly sensitive and reliable tumor-seeking agent for detecting PA, whereas 99mTc-MIBI SPECT is a highly sensitive and specific method in differentiating hormone-secreting pituitary tumor.

show abstract

Section: Discussionsupporting

confidence: 89%

Clinical usefulness of 99mTc-HYNIC-TOC, 99mTc(V)-DMSA, and 99mTc-MIBI SPECT in the evaluation of pituitary adenomas

Vukomanovic¹,

Matović²,

Doknic

et al. 2019

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

“…Aggressive fi bromatosis [1] and squamous cell carcinoma of head and neck cancer [2,3] are also well-known soft tissue tumors that show Tc-99m (V) DMSA uptake. There are also a limited number of reports about positive uptake of Tc-99m (V) DMSA in breast cancer [11], hepatocellular carcinoma [12], and nonfunctioning pituitary adenomas after radiotherapy [13].…”

Section: Discussionmentioning

confidence: 99%

The role of Tc-99m (V) DMSA scintigraphy in the diagnosis and follow-up of lung cancer lesions

et al. 2007

View full text Add to dashboard Cite

show abstract

“…The initial definitive management of pituitary adenomas is almost always surgical, followed by postoperative radiotherapy to reduce the risk of tumor regrowth [74,75]. Colao found that, in addition to a reduction in residual tumor size after radiotherapy, a significant decrease in V DMSA uptake was observed in all patients with a favourable prognosis [76]. In this study, V DMSA appeared to be an easy and repeatable test to assess the viability of pituitary adenomas and to monitor the response to radiotherapy in this tumor type.…”

Section: Phosphate Transport: Technetium 99m-pentavalent Dimercaptosumentioning

confidence: 98%

Spectrum of Radiopharmaceuticals in Nuclear Oncology

Denoyer¹,

Perek²,

Jeune³

et al. 2006

CCDT

View full text Add to dashboard Cite

A major field of interest in nuclear medicine is in vivo tumor characterization and measurement of biological processes at cellular and molecular levels by means of positron emission tomography (PET) or single photon emission computed tomography (SPECT). Functional imaging with radiopharmaceuticals represents a useful noninvasive tool to evaluate the biological status of the tumor and its progression. The properties of radiopharmaceuticals are exploited for initial staging of cancer, assessment of recurrent or residual disease and, more recently, considerable progress has been made in the field of the evaluation of tumor response to treatment. PET and SPECT can both detect changes in tumor activity caused by therapy or disease progression before any detectable change in tumor volume. Measurement of tumor response to therapy using PET and SPECT is the subject of intense investigations because it may result in individualization of treatment and may have a prognostic value for long-term outcome. This review focuses on the various methods used to monitor anticancer therapy with a variety of clinically approved or investigational tracers. We summarize the mechanisms of radiopharmaceutical uptake based on certain physiological activities affected by treatment: proliferation, apoptosis, hypoxia, angiogenesis and multidrug resistance (MDR).

show abstract

^99mTechnetium pentavalent dimercaptosuccinic acid scintigraphy in the follow‐up of clinically nonfunctioning pituitary adenomas after radiotherapy

Abstract: Functional imaging of pituitary remnant adenomas (> 10 mm in size) by (99m)Tc(V)DMSA depicts viable pituitary adenoma remnants. This approach may be of clinical value in patients with clinically nonfunctioning adenomas to monitor the effects of radiotherapy.

Cited by 8 publications

References 31 publications

Clinical usefulness of 99mTc-HYNIC-TOC, 99mTc(V)-DMSA, and 99mTc-MIBI SPECT in the evaluation of pituitary adenomas

Clinical usefulness of 99mTc-HYNIC-TOC, 99mTc(V)-DMSA, and 99mTc-MIBI SPECT in the evaluation of pituitary adenomas

The role of Tc-99m (V) DMSA scintigraphy in the diagnosis and follow-up of lung cancer lesions

Spectrum of Radiopharmaceuticals in Nuclear Oncology

Contact Info

Product

Resources

About